Related Experiment Video

Updated: May 27, 2026

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis

Jeske J Smink1, Per-Ulf Tunn, Achim Leutz

  • 1Max Delbrueck Center for Molecular Medicine, Robert-Roessle-Str.10, 13125 Berlin, Germany.

Journal of Molecular Medicine (Berlin, Germany)
|November 11, 2011
PubMed

Insights

Giant cell tumors (GCTs) involve hyperactive osteoclasts. Targeting the C/EBPβ LIP isoform with rapamycin reduced giant osteoclast formation and bone resorption in GCTs, suggesting a novel therapeutic strategy.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Giant cell tumor (GCT) of bone is characterized by hyperactive osteoclasts leading to osteolytic lesions.
  • The balance between C/EBPβ (CCAAT-enhancer-binding protein beta) LAP and LIP isoforms regulates osteoclast differentiation.
  • Targeting osteoclastogenesis is a potential therapeutic strategy for GCTs.

Purpose of the Study:

  • To investigate the role of C/EBPβ isoforms in GCT-associated giant osteoclast formation.
  • To evaluate the efficacy of mTOR inhibition (rapamycin) in modulating C/EBPβ isoform balance and osteoclast activity in GCTs.

Main Methods:

  • Analysis of C/EBPβ isoform expression in GCTs.
  • Inhibition of mTOR activity using rapamycin in mouse models and patient-derived GCT cell cultures.
  • Assessment of osteoclast differentiation, giant osteoclast formation, and bone resorption.
  • Evaluation of MafB expression.

Main Results:

  • GCTs exhibit high levels of the C/EBPβ LIP isoform, which promotes giant osteoclast formation in mice.
  • Rapamycin treatment decreased osteoclast differentiation by shifting C/EBPβ translation towards the LAP isoform.
  • Rapamycin treatment of patient-derived GCT cells reduced giant osteoclast formation and bone resorption.
  • MafB expression increased following rapamycin treatment.

Conclusions:

  • C/EBPβ isoform ratio is a key determinant of giant osteoclast formation in GCT.
  • Pharmacological modulation of the C/EBPβ isoform ratio, such as with rapamycin, represents a potential therapeutic approach for GCTs.

More Related Videos

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro07:51

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro

Published on: March 18, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...